Histone lysine‐specific demethylase 1 (LSD1) is the first discovered and reported histone
demethylase by Dr. Shi Yang's group in 2004. It is classified as a member of amine oxidase …

In the 10 years since the discovery of lysine‐specific demethylase 1 (LSD1), this epigenetic
eraser has emerged as an important target of interest in oncology. More specifically …

Lysine specific demethylase 1 (LSD1), the first identified histone demethylase, plays an
important role in epigenetic regulation of gene activation and repression. The up-regulated …

Small molecules targeting the flavin adenine dinucleotide (FAD)-dependent histone lysine
demethylase LSD family have displayed therapeutic promise against various diseases. Nine …

The modulation of protein–protein interactions (PPIs) by means of creating or stabilizing
secondary structure conformations is a rapidly growing area of research. Recent success in …

Lysine-specific demethylase 1 (LSD1) is a promising therapeutic target for cancer therapy.
So far, over 80 crystal structures of LSD1 in different complex states have been deposited in …

The lysine-specific histone demethylase 1A (KDM1A) was the first demethylase to challenge
the concept of the irreversible nature of methylation marks. KDM1A, containing a flavin …

Flavin‐dependent, lysine‐specific protein demethylases (KDM1s) are a subfamily of amine
oxidases that catalyze the selective posttranslational oxidative demethylation of methyllysine …

Within the past two decades, seven epigenetic drugs have received regulatory approval and
numerous other candidates are currently in clinical trials. Among the epigenetic targets are …

Synaptic dysfunction is a pathological feature in many neurodegenerative disorders,
including Alzheimer's disease, and synaptic loss correlates closely with cognitive decline …